ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MCRB / insiders
PBM (46) ACTU (35) KYNB (32) AKTX (37) ⌘ Pro Terminal →

Seres Therapeutics Inc. (MCRB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.83 +3.39% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.84

Seres Therapeutics Inc. (MCRB) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $17.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MCRB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Seres Therapeutics Inc. (NASDAQ: MCRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.83 (+3.39% 1D, market cap $17.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, MCRB ranks #469 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MCRB compare to PBM and ACTU in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MCRB carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBM (Psyence Biomedical Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $17.6M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, MCRB leads on earnings multiple (N/A) while MCRB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MCRB?
▼

Per MCRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609809), Seres Therapeutics Inc. generated $789.0K in revenue (-99.8% YoY), $5.7M in net income, and $865.0K in free cash flow against $138.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.84 (+0.42%)🧬 Cannibal Buyback (-0.68% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 86.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (3)SEC (13)Macro (6)CEO (10)
Each axis scored 0–20
12M PRICE TARGET CONE-8.2% Base Target
$31 Bull$2 Base$1 Bear
📬 FREE MCRB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MCRB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY MCRB SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+10/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 50% Net Buy • Cannibal Buyback (-0.68% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$2.53-8.7% Next Q
Q2 (-2Q)
45
Grade D$2.31-22.1% Next Q
Q3 (-1Q)
43
Grade D$1.80+1.7% Next Q
Current
40
Grade D-$1.83-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MCRB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MCRB currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.51) and Max Pain ($1.92) forces dealer call-delta covering toward $31.48.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-0.68% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MCRB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MCRB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

MCRB Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MCRB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MCRB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MCRB)

  • ✓Walkthrough of MCRB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MCRB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -76.20%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.95H $1.95L $1.77C $1.83VOL 120.1K
RES: $3.65SUP: $1.46SMA50: $3.51SMA200: $6.97
$15.36$11.65$7.94$4.23$0.52RES $3.65SUP $1.46$1.832026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MCRB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MCRB Butterfly Map → + Track MCRB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MCRB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MCRB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MCRB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MCRB)

Health Care Rank #469 of 1015 ⚔️ PBM vs MCRB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MCRB vs. PBM, ACTU, KYNB, AKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Seres Therapeutics Inc. (MCRB) ranks #469 by composite RQD confidence (40/100, grade D-) and #836 by equity capitalization ($17.8M). Within this direct 5-issuer industry benchmark cohort, MCRB leads on earnings valuation at N/A trailing P/E, while MCRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with MCRB at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MCRB ACTIVE
Seres Therapeutics Inc.
D- 40/100 — — -35.0% +3.39% $17.8M Benchmark Subject
PBM
Psyence Biomedical Ltd.
D 46/100 — — — -3.93% $17.6M /pbm-vs-mcrb →
ACTU
Actuate Therapeutics Inc.
D- 35/100 — — -35.0% +2.06% $18.4M /actu-vs-mcrb →
KYNB
Kyntra Bio Inc.
E 32/100 — 91.4% -35.0% -2.41% $18.5M /kynb-vs-mcrb →
AKTX
Akari Therapeutics plc ADS
D- 37/100 — — -35.0% -4.85% $18.8M /aktx-vs-mcrb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001609809 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seres Therapeutics Inc. (MCRB) reported GAAP revenue of $789.0K (-99.8% vs. FY2024 revenue of $339.7M , and -99.9% cumulative change since FY2023) , GAAP net income of $5.7M, operating cash flow of $1.1M, and free cash flow of $865.0K (+100.6% YoY). On the balance sheet, MCRB closed FY2025 with $138.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $789.0K $5.7M $1.1M $865.0K $138.2M —
FY2024 (FY) 2024-12-31 $339.7M $136.0K -$148.6M -$149.0M $139.8M —
FY2023 (FY) 2023-12-31 $546.3M -$113.7M -$117.4M -$117.4M — —

3. MCRB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MCRB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Seres Therapeutics Inc. (NASDAQ: MCRB) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.83 (+3.39% 1D, market cap $17.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 10/20. Across 1015 tracked Health Care issuers, MCRB ranks #469 in composite RQD confidence.

How does MCRB compare to PBM and ACTU in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MCRB carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PBM (Psyence Biomedical Ltd.) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $17.6M) and ACTU (Actuate Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $18.4M). Among the 5-stock peer group, MCRB leads on earnings multiple (N/A) while MCRB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MCRB?

Per MCRB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001609809), Seres Therapeutics Inc. generated $789.0K in revenue (-99.8% YoY), $5.7M in net income, and $865.0K in free cash flow against $138.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MCRB trading relative to its 50-day, 200-day, and 52-week technical levels?

MCRB last traded at $1.83 (+3.39% on volume of 44,160 shares), positioning the stock -47.86% below its 50-day simple moving average ($3.51) and -73.74% below its 200-day simple moving average ($6.97). Across its 52-week range of $1.67 to $29.98, MCRB sits at the 0.6% percentile with a 14-day RSI of 26.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.60 to $2.06).

Direct Sub-Reports: MCRB RQD Cockpit MCRB 12M Forecast MCRB Earnings & Move MCRB Dividends & DRIP MCRB Insiders & 13F MCRB Whale Options MCRB Profit Sankey MCRB News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

MCRB — Seres Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Seres Therapeutics Inc. (MCRB) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.83 (+3.39% 1D, market capitalization $17.8M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of 4.42%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 5/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Seres Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The market capitalization is $0.0B. — for product lines, customer base, or revenue model detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Seres Therapeutics Inc. (MCRB) reported $789.0K in annual revenue (up from $339.7M in FY2024, -99.8% YoY) and $5.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($546.3M revenue, -$113.7M net income) through FY2025, MCRB scaled operating cash flow to $1.1M and free cash flow to $865.0K, backed by $138.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 4.42% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.67 – $29.98 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MCRB carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can MCRB sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $789.0K and free cash flow of $865.0K, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MCRB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MCRB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Seres Therapeutics Inc. (MCRB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MCRB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MCRB Bull vs. Bear Conversation Board — What's Your Call at $1.83?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MCRB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MCRB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $2.12 (+19.8%)
📌 Pinned Debate

Forensic balance sheet metrics (Altman Z 2.5, Piotroski F 5/9, Debt/Equity 0.5) and $45.8M cash give the company a relatively stronger

Long MCRB at $1.77 targeting $2.12. Forensic balance sheet metrics (Altman Z 2.5, Piotroski F 5/9, Debt/Equity 0.5) and $45.8M cash give the company a relatively stronger pillar than its operating results.. Institutional whale score is 3/20 and the risk/reward vs. the $1.67 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — MCRB's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $1.50 (-15.3%)
Spot @ $1.77

Operating margin of -60%, ROIC of -35%, and a Whale 13F Flow score of 3 / 20 signal weak economics and little institutional support.

Sitting on the sidelines or leaning short MCRB above $1.77. Operating margin of -60%, ROIC of -35%, and a Whale 13F Flow score of 3 / 20 signal weak economics and little institutional support.. Until Fundamental Cash Engine (8/20) and FCF yield (4.42%) inflect higher, upside is capped near $29.98.

LIVE TAPE